• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Biovail Corp (BVF) - Financial and Strategic Analysis Review Product Image

Biovail Corp (BVF) - Financial and Strategic Analysis Review

  • ID: 1322599
  • August 2010
  • 37 pages
  • GlobalData

FEATURED COMPANIES

  • Elan Corporation, plc
  • IMPAX Laboratories, Inc.
  • MORE

Biovail Corp (Biovail) is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. It uses advanced drug-delivery technologies to improve the clinical effectiveness of medicines. In early 2008, the company adopted a new business model to focus exclusively on treatments for CNS disorder treatment. The company markets its products principally in Canada and the US. Biovail is headquartered at Mississauga in Ontario, Canada.

Biovail Corp Key Recent Developments

Jun 22, 2010 Biovail And MedGenesis Receive $2.1 Million Grant From MJFF For Development Of GDNF
May 06, 2010 Biovail Reports Net Loss Of $3.2 Million For Q1 2010
Feb 25, 2010 Biovail Reports Net Income Of CAD73 Million In Q4 2009
Feb 19, 2010 Biovail Comments On Filing Of Complaints
Feb 10, 2010 Alexza, Biovail Form Collaboration To Develop, Commercialize AZ-004

This comprehensive SWOT profile of Biovail Corp provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the READ MORE >

FEATURED COMPANIES

  • Elan Corporation, plc
  • IMPAX Laboratories, Inc.
  • MORE



List of Tables
List of Figures
Section 1 - About the Company
Biovail Corp - Key Facts
Biovail Corp - Key Employees
Biovail Corp - Key Employee Biographies
Biovail Corp - Major Products and Services
Biovail Corp - History
Biovail Corp - Company Statement
Biovail Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Biovail Corp - Business Description
Biovail Corp- Corporate Strategy
Biovail Corp - SWOT Analysis
SWOT Analysis - Overview
Biovail Corp - Strengths
Strength - Increasing Margins
Strength - Efficient R&D Activities
Biovail Corp - Weaknesses
Weakness - Closure of Dorado, Puerto Rico Facility
Weakness - Limited Investor Confidence
Weakness - Limited Liquidity Position
Weakness - Declining Market Share in Sector
Biovail Corp - Opportunities
Opportunity - Emerging Markets
Opportunity - Aquisitions and License Agreements
Opportunity - Market Potential - CNS Therapy
Opportunity - Successful Implementation of New Business Model
Biovail Corp - Threats
Threat - Uncertain R&D Outcomes
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Intense Competition
Biovail Corp - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Recent Developments
Jun 22, 2010: Biovail And MedGenesis Receive $2.1 Million Grant From MJFF For Development Of GDNF
May 06, 2010: Biovail Reports Net Loss Of $3.2 Million For Q1 2010
Feb 25, 2010: Biovail Reports Net Income Of CAD73 Million In Q4 2009
Feb 19, 2010: Biovail Comments On Filing Of Complaints
Feb 10, 2010: Alexza, Biovail Form Collaboration To Develop, Commercialize AZ-004
Jan 12, 2010: MedGenesis Signs Agreements With Amgen, Biovail
Aug 24, 2009: Santhera Signs License Agreement With Biovail
May 18, 2009: Biovail To Acquire Worldwide Drug Rights
Section 5 - Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

Teva Pharmaceutical Industries Limited
Cubist Pharmaceuticals, Inc.
IMPAX Laboratories, Inc.
Elan Corporation, plc
Medicis Pharmaceutical Corporation
Valeant Pharmaceuticals International

Note: Product cover images may vary from those shown

RELATED PRODUCTS